XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting...( Webcast to Review CUSTOM III Six-Mo...),Health

Webcast to Review CUSTOM III Six-Month Data to be held Tuesday, May 13th

MENLO PARK, Calif., May 7 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that six-month follow-up data from the CUSTOM III trial will be presented at EuroPCR, taking place May 13 to 16 in Barcelona. The company will hold a webcast and conference call to review the new CUSTOM III data immediately following the late-breaking session. In addition, two-year CUSTOM I data, previously presented at the Transcatheter Cardiovascular Therapeutics (TCT) meeting last October, has been accepted for publication in the May issue of EuroIntervention. Professor Grube, the CUSTOM I principal investigator, has been asked to present the data during a EuroPCR session on the six best papers from EuroIntervention. XTENT is also sponsoring an evening symposium on customizable drug-eluting stents and will exhibit throughout the meeting at booth E11 in the main hall.

Schedule of XTENT Events for EuroPCR

Tuesday, May 13, 2008, 3:30-6:30 p.m. CEST, Room 1

Late-Breaking Clinical Trial: CUSTOM III trial 6-month follow-up results.

Bernard de Bruyne, M.D., Ph.D, Cardiovascular Center, OLV Hospital in Aalst, Belgium, the principal investigator of the CUSTOM III clinical trial, will present six-month follow-up data from the CUSTOM III trial evaluating use of the Custom NX(R) Drug Eluting Stent (DES) System in patients with long or multiple coronary lesions.

Tuesday, May 13, 2008, 7:00 p.m. CEST (1:00 p.m. EDT)

CUSTOM III webcast and conference call.

To participate in the conference call, please dial 877-591-4957 (from the U.S.) or 719-325-4895 (international). The webcast and slide presentation can be accessed via the in
'/>"/>